Acute flaccid myelitis and enterovirus D68: lessons from the past and present

Jelte Helfferich1 · Marjolein Knoester2 · Coretta C. Van Leer-Buter2 · Rinze F. Neuteboom3 · Linda C. Meiners4 · Hubert G. Niesters2 · Oebele F. Brouwer1

Received: 19 April 2019 / Revised: 11 July 2019 / Accepted: 16 July 2019 / Published online: 23 July 2019
© The Author(s) 2019

Abstract
Acute flaccid myelitis is characterized by the combination of acute flaccid paralysis and a spinal cord lesion largely restricted to the gray matter on magnetic resonance imaging. The term acute flaccid myelitis was introduced in 2014 after the upsurge of pediatric cases in the USA with enterovirus D68 infection. Since then, an increasing number of cases have been reported worldwide. Whereas the terminology is new, the clinical syndrome has been recognized in the past in association with several other neurotropic viruses such as poliovirus.

Conclusion: This review presents the current knowledge on acute flaccid myelitis with respect to the clinical presentation and its differential diagnosis with Guillain-Barré syndrome and acute transverse myelitis. We also discuss the association with enterovirus D68 and the presumed pathophysiological mechanism of this infection causing anterior horn cell damage. Sharing clinical knowledge and insights from basic research is needed to make progress in diagnosis, treatment, and prevention of this new polio-like disease.

What is Known:
• Acute flaccid myelitis (AFM) is a polio-like condition characterized by rapid progressive asymmetric weakness, together with specific findings on MRI
• AFM has been related to different viral agents, but recent outbreaks are predominantly associated with enterovirus D68.

What is New:
• Improving knowledge on AFM must increase early recognition and adequate diagnostic procedures by clinicians.
• The increasing incidence of AFM urges cooperation between pediatricians, neurologists, and microbiologists for the development of treatment and preventive options.

Keywords  Acute flaccid myelitis · Acute flaccid paralysis · Enterovirus D68 · Poliovirus · Poliomyelitis · Enterovirus

Electronic supplementary material  The online version of this article (https://doi.org/10.1007/s00431-019-03435-3) contains supplementary material, which is available to authorized users.

Jelte Helfferich
j.helfferich@umcg.nl

Marjolein Knoester
m.knoester@umcg.nl

Coretta C. Van Leer-Buter
c.van.leer@umcg.nl

Rinze F. Neuteboom
r.neuteboom@erasmusmc.nl

Linda C. Meiners
l.c.meiners@umcg.nl

Hubert G. Niesters
h.g.m.niesters@umcg.nl

Oebele F. Brouwer
o.f.brouwer@umcg.nl

1 Department of Neurology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, The Netherlands
2 Department of Medical Microbiology and Infection Prevention, Division of Clinical Virology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 Department of Pediatric Neurology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands
4 Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Introduction

Acute flaccid myelitis (AFM) is a syndrome characterized by acute flaccid paralysis (AFP) and gray matter spinal cord lesions on magnetic resonance imaging (MRI). After the introduction of the term AFM in 2014, more than 500 patients, predominantly children, have been recognized both in- and outside Europe [5, 27, 32, 48].

The Center for Disease Control and Prevention (CDC) proposed a case definition in which a definite AFM case is described as acute-onset flaccid weakness, combined with a spinal cord lesion on MRI, largely restricted to the gray matter and spanning one or more spinal segments. Acute flaccid weakness combined with cerebrospinal fluid (CSF) pleocytosis without lesions on MRI is defined as a probable case [4].

A prodromal illness, asymmetric limb weakness, and specific findings in electromyography and nerve conduction studies may further aid in distinguishing AFM from other causes of AFP such as Guillain-Barré syndrome (GBS) and acute transverse myelitis (ATM) [10].

Accumulating evidence supports an association between enterovirus D68 (EV-D68) and AFM [9, 34]. Other viruses that have been associated with outbreaks of acute flaccid weakness and myelitis include enterovirus A71 (EV-A71), West Nile virus (WNV), Japanese encephalitis virus, and the wild-type poliovirus [12, 22, 43, 45].

In this review, we describe the clinical syndrome of AFM, its differential diagnosis, and its association with different viruses, with the emphasis on EV-D68.

Epidemiology

Before the term AFM was introduced, outbreaks of acute flaccid weakness and myelitis, matching the case definition for AFM, were reported in association with EV-A71, predominantly in Eastern Asia and Australia, and with WNV, causing several outbreaks in the USA in the beginning of this century [12, 22]. Poliomyelitis also matches the case definition of AFM and can be seen as the first known cause of AFM. However, MRI was and is often not available in countries where poliomyelitis still occurs, making the definite diagnosis of AFM difficult.

In 2012, the first probable cases were reported in California (USA) [10]. Since 2014, the CDC has reported over 500 cases of AFM in the USA with 2-year intervals and several cohorts of patients with AFM have been reported worldwide (Table 1) [5, 10, 11, 23, 24, 31, 39, 40, 42, 48]. A recent study reported an incidence of 1.46 per 100,000 person years, although reliable data is lacking, as AFM is notifiable in only few countries and the clinical picture is often not recognized [25].

In different cohorts of AFM patients, EV-D68 was detected in 20–40% of cases, primarily from respiratory specimens (Table 1). The variation in detection percentages might be explained by differences in timing and performance of diagnostic procedures and by selection criteria for patients [25]. Most reported patients with AFM were children under the age of 10 with a slight male preponderance. A majority were previously healthy, but asthma was seen in 12–32% of children [25, 33, 48].

Both EV-A71 and West Nile virus are still circulating and have also been detected in recent cohorts of AFM patients [2, 3, 31]. Outbreaks of poliomyelitis are currently rare, due to a global poliovirus surveillance and vaccination program [8].

Clinical features

The clinical characteristics of non-polio AFM cohorts described in literature since 2012 are summarized in Table 1. Muscle weakness typically develops over the course of several hours to days, often with a marked asymmetry. Weakness is proximally usually more severe and may be more pronounced in the upper limbs, with a spectrum of severity varying between slight paresis of a single limb to tetraplegia. Tendon reflexes are typically diminished or absent in the affected limbs. In most patients, there is a prior prodromal illness, often involving the upper respiratory tract, with a median of 5 days before onset of weakness [5, 10, 27, 33].

Methods

For this review, we performed a literature search in PubMed on “flaccid myelitis” and “Enterovirus D68” from 2000 until February 2019. A total of 995 titles of articles in English were screened and selected based on relevance for epidemiology, clinical characteristics, pathophysiology, treatment, prevention, and prognosis of AFM. Only cohorts containing at least five children were selected (Table 1).
Table 1  Summary of cohorts of children of AFM described after 2012, showing patient characteristics, clinical findings, and findings on further investigations

| Author               | Inclusion period | Country/region | No pts | EV-D68 pos | Gender (% male) | Age (mean or median with range) | Prodrome (%) | Limb weakness (%) | Asymmetry (%) | Sensory involvement (%) |
|----------------------|------------------|----------------|--------|------------|-----------------|--------------------------------|---------------|---------------------|---------------|------------------------|
| 1 Andersen 2001–2014| Australia        | 8              | 0% (13% EV-A71) | 25         | Med 5           | 100                           | 100           | 100                 | 100           | 0                      |
| 2 Messacar 2012–2015| USA              | 159            | 20–45% | 56–91      | Med 7.1 (0.4–73) | 64–100                        | 83–100        | 47–70               | 21–44         | 12                     |
| 3 Elrick 2012–2016  | USA              | 34             | 13%    | 65         | Med 5 (<1–15)   | 100                           | 100           | 97                  | 0             | 6                      |
| 4 Yea 2014          | Canada           | 25             | 28%    | 64         | Med 7.8 (0.8–15.0) | 88                           | 100           | NS                  | 12            | 20                     |
| 5 Gordon-Lipkin 2014–2017 | USA     | 159          | 20–45% | 56–91      | Med 4 (3–6)     | 100                           | 100           | 68                  | NS            | 7                      |
| 6 Chong 2015        | Japan            | 59             | 15%    | 59         | Med 4.4 (2.6–77) | 97                           | 100           | 68                  | NS (usual)    | 7                      |
| 7 Knoester 2015–2016| Europe           | 29             | 100%b  | 52         | Med 4 (1.6–55)  | 92                           | 100           | NS                  | NS            | 7                      |
| 8 Bonnitt 2016      | USA              | 10             | 20% (10% EV-A71) | 70         | Med 6 (3–14)    | 80                           | 100           | NS                  | NS            | 7                      |
| 9 Iverson 2016      | USA              | 5              | 60%    | 20         | Mean 7.7 (3.5–12) | 100                          | 100           | NS                  | NS            | 7                      |
| 10 Hübner 2016      | Germany          | 16 (7)d        | 6%     | 50         | Mean 4.6 (1.7-14.3) | 100                         | 100           | 86                  | NS            | 7                      |
| 11 Ruggieri 2016    | Argentina        | 11             | 36%    | 54         | Mean 3.2 (0–3–6) | 100                         | 100           | 81                  | 0             | 0                      |
| 12 Sarmast 2017     | India            | 9              | 0%     | 56         | Med 5.5 (2–7)   | 100                          | 100           | 100                 | 0             | 0                      |
| 13 McKay 2018       | USA              | 80             | 37% (29% EV-A71) | 59         | Med 4 (0.7–32)  | 99                           | 100           | NS                  | NS            | 7                      |
| 14 Ramsay 2018      | UK               | 40 (16)d       | 36%    | 53         | 55% under 5 yo  | 55                           | 98            | NS                  | NS            | 7                      |

| Hyporeflexia (%) | Cranial nerve dysfunction (%) | Ventilatory support (%) | Bowel/bladder dysfunction (%) | CSF pleocytosis (%) | Protein raised in CSF (%) | MRI spine: T2 hyperintensity (%) | Nerve root enhancement (%) | Brainstem lesions |
|------------------|-------------------------------|-------------------------|-------------------------------|---------------------|--------------------------|---------------------------------|--------------------------|-----------------|
| 1 NS             | 25                            | NS                      | 0                             | 85                  | 71                       | 100                             | 38                       | 25              |
| 2 80–81          | 18–83                         | 9–34                    | 18–51                         | 64–91               | 45–58                    | 90–100                          | 20–40                    | 35–75           |
| 3 67             | > 24                          | 24                      | 6                             | 97                  | 45                       | 100                             | 38                       | 62              |
| 4 88             | > 20                          | 28                      | 36                            | 72                  | 28                       | 100                             | 72                       | 32              |
| 5 63             | 50                            | 31                      | NS                            | 100                 | NS (Med 6 g/L)            | 100                             | 13                       | 42              |
| 6 90             | 17                            | 8                       | 27                            | 85                  | 46                       | 100                             | 51                       | 42              |
| 7 87             | 60                            | 66                      | 7                             | 91                  | NS (Med 3.8 g/L)          | 92                             | 16                       | 68              |
| 8 NS             | 30                            | 10                      | 50                            | 78                  | NS (Med 5.8 g/L)          | 100                             | 0                        | 30              |
| 9 NS             | 80                            | NS                      | NS                            | 100                 | NS                       | 80                              | NS                       | NS              |
| 10 NS            | NS                            | 14                      | NS                            | 43                  | NS                       | 86                              | NS                       | NS              |
| 11 100           | 45                            | 36                      | 0                             | 63                  | 18                       | 100                             | NS                       | 45              |
| 12 100           | 11                            | NS                      | 0                             | 89                  | 22                       | 100                             | NS                       | 11              |
| 13 NS            | NS                            | NS                      | NS                            | 83                  | NS (Med 4.7 g/L)          | 100                             | NS                       | NS              |
| 14 NS            | NS                            | 55                      | NS                            | 18                  | NS                       | 43                              | NS                       | NS              |

No pts, number of patients; EV-D88, enterovirus D68; EV-A71, enterovirus A71; med, median; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; USA, United States of America; UK, United Kingdom; NS, not specified; yo, year old.

a Combination of four US cohorts with a partial overlap in these cohorts.
b EV-D68 had to be identified for inclusion.
c 16 registered cases, 7 of which were further described.
d 40 cases of Acute Flaccid Paralysis, of which 16 fulfilled the criteria for probable or definite AFM.
Weakness can be limited to the extremities, but the diaphragm and bulbar muscles may also be affected, making ventilatory support necessary in the acute phase in about 30% of cases [10, 13, 33, 48]. Cranial nerve deficits are common and may be the only finding. The facial nerve is most often affected, followed by the abducens and oculomotor nerves [33].

Associated features include severe limb pain and autonomic disturbances such as bladder dysfunction. Sensory symptoms, primarily paresthesia, are reported in up to 20% of cases [5, 10, 27, 33].

The clinical features of cohorts of AFM, described before 2012, associated with EV-A71, WNV, and poliovirus were highly similar, although poliovirus-related AFM more often affected lower limbs, with bulbar muscles usually being spared [43]. EV-A71 has also been associated with rhombencephalitis, sometimes with severe cardiorespiratory symptoms [12, 22, 43].

Differential diagnosis

AFM is included in the broad differential diagnosis of AFP. AFP is defined as a syndrome of focal weakness of peripheral origin in any part of the body with an acute onset [30].

It is important to be able to recognize AFM early in its course so that adequate diagnostic procedures can be performed and respiratory failure in the initial phase can be anticipated. Both clinical clues and findings on further investigations may help differentiate AFM from other causes of AFP.

In cases of AFM in which only one arm is affected, the initial thought may be that of synovitis or arm injury. Clinical clues that may help in distinguishing these from AFM may be the presence of a prodromal illness, the hypo- or areflexia, and the often-associated neck weakness in AFM.

When more than one limb is affected, the differential diagnosis includes other causes of acute myelopathy, such as acute transverse myelitis (ATM), acute disseminated encephalomyelitis (ADEM), acute cord compression, and ischemic myelopathy. Furthermore, Guillain-Barré syndrome (GBS) may be suspected because of the sudden onset of flaccid weakness after a prodromal illness.

While the asymmetric weakness, the absence of encephalopathy, the paucity of sensory symptoms, and the presence of cranial nerve deficits in AFM may help in distinguishing it from other causes of AFM, further investigations are required to make the right diagnosis (Table 2; Figs. 1, 2, 3, 4) [1, 10, 20, 33, 47].

Investigations

Diagnostic tests recommended in children with suspected AFM should be directed at the identification of different microorganisms and the exclusion of other causes (Table 3) [15]. Initial investigations must be performed on blood, stool, respiratory material, and CSF, followed by MRI of the brain and spinal cord and in some cases electromyography (EMG).

Blood

General laboratory investigation of blood samples of AFM patients may show a slight leukocytosis, sometimes with raised inflammatory parameters, which is usually not helpful in the differentiation of AFM from other disorders causing AFP [20, 33].

Cerebrospinal fluid

CSF examination in AFM patients in the described cohorts since 2012 reveals a mild to moderate pleocytosis in most cases (Table 1). Protein levels are initially minimally raised in about half of AFM cases but can be completely normal.

After several days, the leukocyte number tends to decrease, while protein levels rise [5, 14, 27, 33]. Oligoclonal bands in the CSF can be identified in immune-mediated conditions such as ATM, but are usually not found in AFM [1].

Interestingly, viral agents, such as EV-D68, EV-A71, and poliovirus, are only detected in the CSF in a small minority of patients with AFM [5, 22, 27, 40, 43].

Virology diagnostic testing

The viral RNA of EV-D68 is detected mostly in respiratory samples, followed to a much lesser extent by feces and can only rarely be found in blood or CSF. This in contrast to EV-A71, which is more frequently detected in blood, and poliovirus, which is routinely identified in stool samples [15, 43].

Obtaining an adequate respiratory sample is therefore indispensable for detection of EV-D68. Considering the fact that the prodromal, mostly respiratory illness is usually a few days into its natural course when a patient presents with weakness, the best chances of detecting EV-D68 is soon after onset of complaints. Several PCR tests have been described, which test either directly for EV-D68 or for enteroviruses in general [15, 38].

Magnetic resonance imaging

MRI of the brain and spinal cord is important in making the diagnosis of AFM and in distinguishing it from other causes of AFP (Table 2 and Figs. 1, 2, 3, 4) [13]. CT usually shows no abnormalities [28].

In AFM, the classical MRI feature is a longitudinally extensive slight T2-hyperintense signal in the central cord, affecting the central gray matter, often more pronounced in the cervical regions (Fig. 1b, c). Initially, there is usually more diffuse spinal cord edema, evolving over several days to T2-
myelitis is known, but is estimated to be less than 1%, similar to polio-infected patients afflicted with paralytic disease is not yet indicate a better prognosis [5, 21, 33].

The persistence of F-waves may decreased compound muscle action potentials (CMAP) with normal conduction velocities. Sensory testing is usually creased with anterior horn damage that is probably caused by a direct damaging effect on muscles through viral myositis.

Fluid retention of the caudal roots and sometimes of the cranial nerves can be seen (Fig. 1d) [28].

MRI of the brain commonly reveals an area of slight hyperintensity typically located in the dorsal pons in the region of the nuclei of the abducens and facial nerve. The corticospinal tracts, located ventrally, are not affected (Fig. 1a), while the caudate nucleus may be involved [28]. These findings may help in securing the diagnosis, but the correlation between symptoms and radiologic findings is usually poor, making MRI unsuitable as a prognostic tool for AFM [37].

Imaging findings in earlier outbreaks of AFM, associated with WNV and poliovirus, were highly similar, while in EV-A71–associated neurological disease, these appear to be more variable and more extensive brain abnormalities may occur [6, 12, 22].

Neurophysiological studies

While EMG findings in recent outbreaks of AFM can be normal on the first day, after several days, a pattern compatible with anterior horn disease is seen. This encompasses decreased compound muscle action potentials (CMAP) with anterior horn disease. The persistence of F-waves may indicate a better prognosis [5, 21, 33].

Virology

Enteroviruses, such as EV-D68, EV-A71, and poliovirus, are small RNA viruses belonging to the picornavirus family. EV-D68 was first identified in 1962 after isolation from children with severe respiratory disease [44]. Since 2012, an increasing incidence has been recognized, with infections mostly occurring in autumn and late summer. EV-D68 appears to occur in a cyclic pattern with a 2-year interval [27, 34].

EV-D68 infection may be asymptomatic or cause respiratory disease. In hospitalized children, an asthma-like respiratory disease is most commonly seen [39]. The percentage of infected patients afflicted with paralytic disease is not yet known, but is estimated to be less than 1%, similar to poliomyelitis [29, 43].

Pathophysiology

A causal relationship between EV-D68 and AFM is supported by epidemiological and biological evidence, as was evaluated by different groups applying the Bradford Hill criteria [9, 34].

The biological evidence mainly came from mouse models, in which mice infected with contemporary circulating strains of EV-D68 develop flaccid paralysis mimicking AFM. Interestingly, neonatal or young mice are used, because older mice are not susceptible to disease [17, 36]. Pathologic examination of infected mice revealed the presence of the virus in the anterior horn with associated cell loss [17, 36]. EV-D68 probably reaches the anterior horn by retrograde axonal transport, as is supported by both mouse studies and in vitro studies in human motor neurons [17, 19, 36].

One study found myositis without spinal cord infection after intranasal injection of the virus in mice [36].

Although the results from mouse studies cannot simply be extrapolated to humans, these results are suggestive of a damaging effect of the virus in anterior horn cells, possibly combined with a direct damaging effect on muscles through viral myositis.

Important questions remain why only some EV-D68 infected patients develop AFM and how the variability in severity of AFM in affected patients is explained.

Treatment

There are currently no effective treatment options for AFM. Most patients are treated with intravenous immunoglobulin (IVIG), steroids, or plasmapheresis, or a combination, but no significant clinical effect of any of these interventions has been shown so far. Because of its effectiveness in the mouse model of EV-D68–associated AFM and its possible efficacy in treatment of EV-A71–associated encephalomyelitis, treatment with IVIG has been recommended [18, 33, 46, 48].

The anti-inflammatory effects of steroids may be beneficial in AFM cases with spinal cord edema or white matter involvement, but steroids are unlikely to be effective in limiting the anterior horn damage that is probably caused by a direct damaging effect of the virus. Furthermore, treatment with steroids in a mouse model of AFM associated with EV-D68 led to an increased viral load and a deterioration of motor symptoms [17, 36].

Fluoxetine, an antidepressant, is effective in inhibiting EV-D68 replication in vitro. However, treatment with fluoxetine in the mouse model of EV-D68–associated AFM did not result in reduction of the viral load or improvement of motor function. Also, no significant effect has been shown in patients with AFM, treated with fluoxetine [18, 35].

While scientific proof is still lacking, we recommend IVIG in the acute phase, combined with maximal supportive care with optimal pain control, feeding, ventilatory support, and intensive rehabilitation. Surgical procedures such as nerve and muscle transfers have been performed and cases have been described in which improvement of limb function has been achieved. Because over time degeneration of the receiving motor nerves and muscle fibers will occur, evaluation for
### Table 2  Signs, symptoms and findings on further investigations in acute flaccid myelitis, Guillain-Barré syndrome, and acute transverse myelitis

|                                | Acute flaccid myelitis (with EV-D68) | Guillain-Barré syndrome | Acute transverse myelitis |
|--------------------------------|--------------------------------------|-------------------------|---------------------------|
| **Prodrome**                   |                                      |                         |                           |
| Type                           | Febrile illness often with respiratory and/or gastrointestinal symptoms | Febrile illness often with gastrointestinal symptoms and or respiratory symptoms | Commonly a preceding febrile illness |
| Time until onset of weakness   | Usually within 1 week                | Several weeks           | Days to weeks             |
| **Clinical details**           |                                      |                         |                           |
| Neurologic deficits            | Asymmetric flaccid weakness, with upper limbs often more affected, proximal > distal | Ascending weakness, lower limbs > upper limbs | Symmetric weakness, may be asymmetric initially |
| Reflexes                       | Typically low or absent              | Low or absent           | Usually high, can be low initially |
| Sensory symptoms               | Typically no sensory deficits        | Paresthesia and slight distal sensory symptoms (except in AMAN) | Common, often with a sensory level |
| Cranial nerve deficits         | Bulbar weakness and asymmetric facial palsy common; sometimes oculomotor deficits | Symmetric facial weakness; oculomotor deficits in MFS | None |
| Other symptoms                 | Pain, autonomic dysfunction          | Pain, autonomic dysfunction | Bowel and bladder dysfunction |
| Time course                    | Progressive over hours to days       | Progressive symptoms over several days | Progressive over 4 h to 21 days |
| **Findings**                   |                                      |                         |                           |
| CSF                            | Slight pleocytosis, raised protein. May be completely normal | Raised protein after several days, without pleocytosis (“dissociation cytoalbuminique”) | Slight pleocytosis, raised protein. May be completely normal |
| Microbiology                   | EV-D68 in respiratory specimen      | Campylobacter jejuni in feces; EBV, CMV, HEV, Zika virus in blood | Usually none |
| MRI brain                      | Typical T2-hyperintense region in the dorsal pons, sometimes also in caudate nuclei. Cranial nerve enhancement possible | Normal | Normal |
| MRI spine                      | Longitudinally extensive diffuse slightly hyperintense central cord lesion, usually most pronounced in the cervical region. Sometimes cauda equina root enhancement | Cauda equina root enhancement may be found | Central cord focal hyperintense lesion over multiple levels affecting white and gray matter |
| EMG                            | Findings of motor axonopathy with low CMAPs, normal NCV. Normal sensory findings | Decreased NCV with blocks are typical. Normal sensory findings in AMAN | Normal |
| Treatment/prognosis            |                                      |                         |                           |
| Treatment                      | No effective treatment, potential positive effect of IVIG | IVIG and/or plasmapheresis effective | High-dose steroids, sometimes IVIG and/or plasmapheresis |
| Prognosis                      | Improvement over several months, but often significant residual weakness and muscle atrophy | Often complete recovery over the course of weeks until months | Partial recovery over the course of months until years |

**EV-D68**, enterovirus D68; **AMAN**, acute motor axonal neuropathy; **MFS**, Miller Fisher syndrome; **EBV**, Epstein Barr virus; **CMV**, cytomegalovirus; **HEV**, hepatitis E virus; **CMAP**, compound muscle action potential; **NCV**, nerve conduction velocity; **IVIG**, intravenous immunoglobulin
surgical intervention should be considered early in the disease course [41].

**Prevention/vaccination**

In the mouse model of EV-D68–associated AFM, passive immunization with pooled immune sera, if administered before injection of the virus, was effective in decreasing the rate of paralysis [18]. Arguments for vaccination as a treatment strategy arise from the development of effective vaccines against EV-A71 infections in China and the effective eradication of poliomyelitis in most of the world after introduction of vaccination [8, 49]. Recently, an experimental vaccine based on virus-like particles targeting EV-D68 has been developed. This vaccine has been proven effective in a mouse model in the prevention of AFM [7].

**Prognosis**

Only 5–39% of patients with AFM recover partially to completely (supplementary table 1). Most patients retain...
**Fig. 3** MRI of the spinal cord in a 15-year-old boy with acute transverse myelitis, eventually diagnosed with relapsing remitting multiple sclerosis. 

- **a** Sagittal T2 showing focal swelling of the spinal cord at level Th11–12. 
- **b** Sagittal T1 showing contrast enhancement of the lesion.

**Fig. 4** MRI of a 13-year-old boy with a provisional diagnosis of acute demyelinating encephalomyelitis. 

- **a** Sagittal short tau inversion recovery (STIR) with edematous cervicothoracic spinal cord from the level of C4. 
- **b** Sagittal T1 of the spinal cord showing diffuse areas of slight enhancement. 
- **c** Enhancement of mainly dorsal roots in a sagittal T1 of the lumbar spine. 
- **d** and **e** Transverse T2 at the level of the pons (**d**) and thalamus (**e**) showing asymmetric hyperintense areas.
Table 3  Suggested workup for children with acute flaccid paralysis

| Blood          | Routine investigations (blood count, inflammatory parameters, creatine kinase, liver and renal function tests) |
|----------------|---------------------------------------------------------------------------------------------------------|
|                | Auto-antibodies (anti-MOG IgG, anti-AQP4, anti-GM1, anti-GQ1b)                                         |
|                | Oligoclonal bands (both serum and CSF)                                                                   |
|                | Microbiology: testing for enterovirus (including poliovirus), EBV, CMV, VZV, HEV, Zika virus*             |
| CSF            | Routine investigations (cell count, protein, glucose)                                                    |
|                | Oligoclonal bands (both CSF and serum)                                                                   |
|                | Microbiology: testing for enterovirus, parechovirus, HSV, VZV, EBV                                       |
| Further microbiologic testing | Nasopharyngeal swab for enterovirus testing                                                            |
|                | Stool sample for enterovirus and C. jejuni testing                                                      |
| Imaging        | Contrast-enhanced MRI of the brain and spine                                                            |
| Neurophysiologic testing | EMG with motor and sensory investigation of an affected limb                                          |

MOG, myelin-oligodendrocyte glycoprotein; AQP4, aquaporin 4; GM1, ganglioside M1; GQ1b, ganglioside Q1b; EBV, Ebstain Barr virus; CMV, cytomegalovirus; VZV, Varicella Zoster virus; HEV, hepatitis E virus; CSF, cerebrospinal fluid; HSV, Herpes Simplex virus; EMG, electromyography

*For patients that have traveled to or live in countries where Zika virus is prevalent

significant residual motor deficits, and prolonged need for ventilatory support is not uncommon. On follow-up, residual proximal weakness tends to be more severe than distal weakness, with severe atrophy occurring over time [5, 13, 23, 26, 29, 48]. Cranial nerve deficits usually recover well over time. Death is uncommon but has been reported in immunocompromised patients, usually because of respiratory complications [27, 33]. While not much is known about prognostic factors, more severe disability and weakness at nadir and the persistence of denervation seem to be associated with worse outcome. One study found a correlation between negative tests for EV-D68 at onset and better outcome, which made the authors speculate that viral clearance and host responses play a role in the severity of weakness in AFM [5]. Alternatively, these EV-D68–negative cases may be due to different etiologies associated with more favorable outcomes than cases confirmed to be associated with EV-D68.

Conclusion and future perspectives

AFM is a newly introduced term comprising AFP combined with longitudinally extensive lesions of the spinal cord on MRI. This syndrome resembles poliomyelitis and has been associated with different viruses, in particular EV-D68.

EV-D68 infection is usually asymptomatic or mildly symptomatic with respiratory illness, but it can be associated with anterior horn disease causing severe weakness, with only minimal improvement over time in most cases.

A major challenge lies in the propagation of correct diagnostic procedures, including viral testing on respiratory material in suspected AFM cases. Future research may identify risk factors for AFM in EV-D68–infected patients and will elucidate how these factors can be influenced.

We believe that worldwide collaboration between neurologists, radiologists, pediatricians, and microbiologists is necessary to make progress in preventing and treating this devastating childhood disease. Furthermore, we postulate that making AFM a notifiable disease in more countries can increase awareness among clinicians and governments.

Authors’ Contributions  J. Helfferich drafted and revised the manuscript. M. Knoester, C.C. van Leer-Buter, R.F. Neuteboom, L.C. Meiners and H.G.M. Niesters critically revised the manuscript. O.F. Brouwer critically revised the manuscript and supervised the writing of the manuscript. All authors gave final approval.

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflict of interest.

Informed consent  Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Absoud M, Greenberg BM, Lim M et al (2016) Pediatric transverse myelitis. Neurology 87:S46–S52. https://doi.org/10.1212/WNL.0000000000002820
2. Andersen EW, Kornberg AJ, Freeman JL et al (2017) Acute flaccid myelitis in childhood: a retrospective cohort study. Eur J Neurol 24: 1077–1083. https://doi.org/10.1111/ene.13345
3. Bonwitt J, Poel A, DeBolt C et al (2017) Acute flaccid myelitis among children - Washington, September–November 2016. MMWR Morb Mortal Wkly Rep 66:826–829. https://doi.org/10.15585/mmwr.mm6631a2
4. CDC (2017) Revision to the standardized surveillance and case definition for acute flaccid myelitis
5. Chong PF, Kira R, Mori H et al (2018) Clinical features of acute flaccid myelitis temporally associated with an enterovirus D68 outbreak: results of a nationwide survey of acute flaccid paralysis in Japan, August–December 2015. Clin Infect Dis 66:653–664. https://doi.org/10.1093/cid/cix860
6. Choudhary A, Sharma S, Sanikhyan N et al (2010) Midbrain and spinal cord magnetic resonance imaging (MRI) changes in polio-myelitis. J Child Neurol 25:497–499. https://doi.org/10.1177/0883073099340918
7. Dai W, Zhang C, Zhang X et al (2018) A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine 36:653–659
8. Derrough T, Salekeen A (2016) Lessons learnt to keep Europe polio-free: a review of outbreaks in the European Union, European Economic Area, and candidate countries, 1973 to 2013. Euro Surveill 21:https://doi.org/10.2807/1560-7917.ES.2016.21.16.30210
9. Dyda A, Stelzer-Braids S, Adam D, et al (2018) The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the evidence for causation? Euro Surveill 23:https://doi.org/10.2807/1560-7917.ES.2018.23.3.00310
10. Elrick MJ, Gordon-Lipkin E, Crawford TO et al (2019) Clinical subpopulations in a sample of North American children diagnosed with acute flaccid myelitis, 2012–2016. JAMA Pediatr 173:134–139. https://doi.org/10.1001/jamapediatrics.2018.4890
11. Force TUKAFPAT (2019) An increase in reports of acute flaccid myelitis, 2012–2016. J Infect Dis 216:1245–1253. https://doi.org/10.1093/infdis/jix468
12. Glass JD, Samuels O, Rich MM (2002) Poliomyelitis due to West Nile virus. N Engl J Med 347:1280–1281. https://doi.org/10.1056/NEJM200210173471616
13. Gordon-Lipkin E, Munoz LS, Klein JL et al (2018) Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease. Dev Med Child Neurol 61:366–375. https://doi.org/10.1111/dmcn.14030
14. Greensinger AL, Naccache SN, Messacar K et al (2015) A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00093-9
15. Harvala H, Broberg E, Benschop K et al (2018) Recommendations for enterovirus diagnostics and characterisation within and beyond European Economic Area, and candidate countries, 1973 to 2013. Euro Surveill 21:https://doi.org/10.2807/1560-7917.ES.2018.21.1.35714
16. Hovden IA, Pfeiffer HC (2015) Electrodiagnostic findings in acute flaccid myelitis related to enterovirus D68. Muscle Nerve 52:909–910. https://doi.org/10.1002/mus.24738
17. Hubner J, Kruse B, Christen HJ et al (2017) Acute flaccid myelitis in German children in 2016-the return of polio? Dtsch Arztebl Int 114:551–557. https://doi.org/10.3238/arztebl.2017.0551
18. Iverson SA, Ostdiek S, Prasai S et al (2017) Notes from the field: cluster of acute flaccid myelitis in five pediatric patients - Maricopa County, Arizona, 2016. MMWR Morb Mortal Wkly Rep 66:758–760. https://doi.org/10.15585/mmwr.mm6628a4
19. Kane MS, Sonne C, Zhu S et al (2019) Incidence, risk factors and outcomes among children with acute flaccid myelitis: a population-based cohort study in a California Health Network between 2011 and 2016. Pediatr Infect Dis J 38:667–672. https://doi.org/10.1097/INF.0000000000002276
20. Kirollos A, Mark K, Shetty J et al (2018) Outcome of paediatric acute flaccid myelitis associated with enterovirus D68: a case series. Dev Med Child Neurol 61:376–380. https://doi.org/10.1111/dmcn.14096
21. Knoester M, Helfferich J, Poelmans R et al (2019) Twenty-nine cases of enterovirus-D68-associated acute flaccid myelitis in Europe 2016: a case series and epidemiologic overview. Pediatr Infect Dis J 38:16–21. https://doi.org/10.1097/INF.0000000000002188
22. Maloney JA, Mirkys DM, Messacar K et al (2014) MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. Am J Neuroradiol 36:245–250. https://doi.org/10.3174/ajnr.A4188
23. Martin J, Messacar K, Yang ML et al (2017) Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology 89:129–137. https://doi.org/10.1212/WNL.0000000000004081
24. Marx A, Glass JD, Sutter RW (2000) Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev 22:298–316
25. McKay SL, Lee AD, Lopez AS et al (2018) Increase in acute flaccid myelitis - United States, 2018. MMWR Morb Mortal Wkly Rep 67:1273–1275. https://doi.org/10.15585/mmwr.mm6745e1
26. Messacar K, Schreiner TL, Maloney JA et al (2015) A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet (London, England) 385:1662–1671. https://doi.org/10.1016/s0140-6736(14)63623-5
27. Messacar K, Schreiner TL, Van Haren K et al (2016) Acute flaccid myelitis: a clinical review of US cases 2012–2015. Ann Neurol 80:326–338. https://doi.org/10.1002/ana.24730
28. Messacar K, Asturias EJ, Hixon AM et al (2018) Outbreaks of enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality. Lancet Infect Dis 18:e239–e247. https://doi.org/10.1016/S1473-3099(18)30094-X
29. Messacar K, Sillau S, Hopkins SE et al (2018) Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology 92:e2118–e2126. https://doi.org/10.1212/201701000146257-0
30. Okumura A, Mori H, Fee Chong P et al (2018) Serial MRI findings of acute flaccid myelitis during an outbreak of enterovirus D68 infection in Japan. Brain and Development 41:443–451. https://doi.org/10.1016/j.braindev.2018.12.001
31. Poelman R, Scholvink EH, Borger R et al (2015) The emergence of enterovirus D68 in a Dutch University Medical Center and the...
necessity for routinely screening for respiratory viruses. J Clin Virol 62:1–5. https://doi.org/10.1016/j.jcv.2014.11.011

39. Rao S, Messacar K, Torok MR et al (2016) Enterovirus D68 in critically ill children: a comparison with pandemic H1N1 influenza. Pediatr Crit Care Med 17:1023–1031. https://doi.org/10.1097/PCC.0000000000000922

40. Ruggieri V, Paz MI, Peretti MG et al (2017) Enterovirus D68 infection in a cluster of children with acute flaccid myelitis, Buenos Aires, Argentina, 2016. Eur J Paediatr Neurol 21:884–890

41. Saltzman EB, Rancy SK, Sneag DB et al (2018) Nerve transfers for enterovirus D68-associated acute flaccid myelitis: a case series. Pediatr Neurol 88:25–30

42. Sarmast SN, Gowda VK, Ahmed M et al (2018) Acute flaccid myelitis-clustering of polio-like illness in the tertiary care centre in Southern India. J Trop Pediatr. https://doi.org/10.1093/troped/ fmy052

43. Scheld WM, Marra CM, Whitley RJ (2004) Chapter 7: poliomyelitis, polio vaccines, and the postpoliomyelitis syndrome. In: J G (ed) 4th ed. Wolters Kluwer, Philadelphia, pp 112–124

44. Schieble JH, Fox VL, Lennette EH (1967) A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 85:297–310

45. Solomon T, Kneen R, Dung NM et al (1998) Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (London, England) 351:1094–1097

46. Wang SM, Lei HY, Huang MC et al (2006) Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 37:47–52

47. Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barre syndrome. Lancet (London, England) 388:717–727. https://doi.org/10.1016/S0140-6736(16)00339-1

48. Yea C, Bitnun A, Robinson J et al (2017) Longitudinal outcomes in the 2014 acute flaccid paralysis cluster in Canada. J Child Neurol 32:301–307. https://doi.org/10.1177/0883073816680770

49. Zhu F, Xu W, Xia J et al (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370:818–828. https://doi.org/10.1056/NEJMoa1304923

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.